Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BR790 Monotherapy in Advanced Solid Tumors
NCT04891653Phase 1Unknown
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- Start
- Jun 2021
- Primary completion
- Jun 2023
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of BR790 in solid tumor (advanced stage), sponsored by Jiangxi Qingfeng Pharmaceutical Co. Ltd. Primary endpoints: Dose limiting toxicity up to 32 days, Maximum tolerated dose up to 32 days and 1 more. Status: unknown.
02
Drugs
BR790
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04891653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04891653.